Resources
26 Results (showing 1 - 10)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 11/19/2019 (updated 3/25/2024)
Although typically delivered via intramuscular or intravenous injection, naloxone may be delivered via intranasal spray device.
Posted 4/27/2020 (updated 3/28/2024)
To mitigate the opioid overdose crisis, states have implemented a variety of legal interventions aimed at increasing access to the opioid antagonist naloxone. Recently, Virginia and Vermont mandated the coprescription of naloxone for potentially at-risk patients.
Posted 5/22/2020 (updated 3/28/2024)
As a response to the ongoing opioid crisis, every US state has increased access to naloxone through a variety of expanded prescribing methods, such as standing orders or protocols. This reports examines the impact of a standing order for rural Georgia pharmacies.
Posted 10/12/2020 (updated 3/29/2024)
The present two-fold study “Speed Limits – Harm reduction for people who use stimulants” significantly contributes to closing the gap of knowledge about which existing harm reduction interventions are effective for people who use stimulant drugs.
Posted 10/23/2020 (updated 4/3/2024)
These pilot study results suggest comparable safety and effectiveness of unobserved and office induction and point toward utilization of non-inferiority design during future definitive protocol development.
Posted 10/23/2020 (updated 4/3/2024)
This article offers data regarding offering buprenorphine treatment at a public hospital primary care setting using a home, unobserved induction protocol.
Posted 12/29/2020 (updated 4/4/2024)
Whereas outpatient treatment with medication for opioid use disorder (MOUD) is evidence based, there is a large network of inpatient facilities in the US that are reimbursed by commercial insurers and do not typically offer MOUD. This study is a comparison of rates of overdose and hospitalization after initiation of medication for Opioid Use Disorder in the inpatient vs outpatient setting.
Posted 2/18/2021 (updated 4/4/2024)
Opioid use disorder (OUD), a chronic disease, is a major public health problem. Despite availability of effective treatment, too few people receive it and treatment retention is low. Understanding barriers and facilitators of treatment access and retention is needed to improve outcomes for people with OUD.
In this study we sought to assess 3-month outcomes from a patient-centered practice that included MAT with buprenorphine or naltrexone plus the option to participate in psychosocial treatments. The psychosocial treatments included case management, psychotherapy, peer recovery groups such as Narcotics Anonymous or Smart Recovery, or peer support through a local harm reduction program.
Posted 3/5/2021 (updated 4/5/2024)
The United States is facing a crisis of opioid-related overdose. At this time, more people die of overdose every year than died of AIDS at the peak of the HIV epidemic. Communities seek effective responses to prevent opioid death.
Posted 4/28/2021 (updated 4/10/2024)
Many people use opioids and are at risk of overdose. Naloxone is an opioid antagonist used to counter the effects of opioid overdose. There is an increased availability of naloxone in New York City; however, many who use opioids decline no-cost naloxone even when offered. Others may have the medication but opt not to carry it and report that they would be reluctant to administer it if they were to witness an overdose.